Medicare upholds anemia drug cuts

Medicare to Johnson & Johnson and Amgen: You can't always get what you want. Dealing a blow to both companies' fortunes, the agency says it won't reverse its decision to cut reimbursements for anemia drugs.

The two companies surely got their hopes up last week when an FDA advisory committee recommended against dosage restrictions on the drugs, which include Amgen's Aranesp and J&J's Procrit. Shareholders certainly did; Amgen's stock skyrocketed on the news.

There's a loophole, though. Medicare said it might change its mind if the companies came up with some proof that chemo patients absolutely need the drugs. New clinical trial, anyone?

- read the article from the Boston Globe

Suggested Articles

Now that Teva's Ajovy has an autoinjector FDA approval to match its rivals, can the drug actually score the 25% market share execs are hoping for?

Social media mavens do it for the gram, but the FDA wants know whether consumers give a care about paid endorsements.

Pfizer's diagnosis-focused launch strategy for Vyndaqel and Vyndamax is paying off with the meds reaching thousands of patients already.